P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

Slični predmeti

• P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
  od: J. Martínez-López, i dr.
  Izdano: (2022-06-01)
• P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
  od: R Popat, i dr.
  Izdano: (2022-04-01)
• P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
  od: Surbhi Sidana, i dr.
  Izdano: (2023-08-01)
• TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
  od: NWCJV Donk, i dr.
  Izdano: (2023-10-01)
• Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
  od: Niels W. C. J. van de Donk, i dr.
  Izdano: (2024-10-01)